Novartis Pharmaceuticals Corp

3 of its medicines lose their last listed patent or exclusivity between January 1, 2026 and December 31, 2027.

January 13, 2026Promactaeltrombopag olamine
January 13, 2026Promacta Kiteltrombopag olamine
February 13, 2026Egatentriclabendazole

Dates are the patent and exclusivity end dates listed in the FDA's Orange Book, in its data up to October 9, 2026. Patents can be extended, challenged in court or settled, so a generic may come earlier, later or not at all. This is not legal or medical advice.

About the data·Privacy·Credits